- Home
- OTLK vs ANTX Comparison
OTLK vs ANTX Comparison
Compare OTLK & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLK
- ANTX
- Stock Information
- Founded
- OTLK 2010
- ANTX 2017
- Country
- OTLK United States
- ANTX United States
- Employees
- OTLK N/A
- ANTX N/A
- Industry
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- ANTX Biotechnology: Pharmaceutical Preparations
- Sector
- OTLK Health Care
- ANTX Health Care
- Exchange
- OTLK Nasdaq
- ANTX Nasdaq
- Market Cap
- OTLK 38.7M
- ANTX 41.2M
- IPO Year
- OTLK 2016
- ANTX 2022
- Fundamental
- Price
- OTLK $1.20
- ANTX $1.27
- Analyst Decision
- OTLK Strong Buy
- ANTX Hold
- Analyst Count
- OTLK 5
- ANTX 5
- Target Price
- OTLK $10.20
- ANTX $3.50
- AVG Volume (30 Days)
- OTLK 374.0K
- ANTX 84.2K
- Earning Date
- OTLK 05-14-2025
- ANTX 05-13-2025
- Dividend Yield
- OTLK N/A
- ANTX N/A
- EPS Growth
- OTLK N/A
- ANTX N/A
- EPS
- OTLK N/A
- ANTX N/A
- Revenue
- OTLK N/A
- ANTX N/A
- Revenue This Year
- OTLK N/A
- ANTX N/A
- Revenue Next Year
- OTLK $288.46
- ANTX N/A
- P/E Ratio
- OTLK N/A
- ANTX N/A
- Revenue Growth
- OTLK N/A
- ANTX N/A
- 52 Week Low
- OTLK $0.87
- ANTX $0.87
- 52 Week High
- OTLK $9.98
- ANTX $3.19
- Technical
- Relative Strength Index (RSI)
- OTLK 34.06
- ANTX 40.51
- Support Level
- OTLK $1.15
- ANTX $1.28
- Resistance Level
- OTLK $1.31
- ANTX $1.42
- Average True Range (ATR)
- OTLK 0.12
- ANTX 0.08
- MACD
- OTLK -0.01
- ANTX -0.02
- Stochastic Oscillator
- OTLK 20.45
- ANTX 0.00
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.